Cronnelly R, Stanski D R, Miller R D, Sheiner L B
Clin Pharmacol Ther. 1980 Jul;28(1):78-81. doi: 10.1038/clpt.1980.134.
Pyridostigmine kinetics were examined under conditions of clinical use as an antagonist of nondepolarizing neuromuscular blockade in anesthetized patients with and without renal function. Pyridostigmine serum levels were assayed by gas-liquid chromatography, and data were fitted to a 2-compartment kinetic model. Pyridostigmine kinetics following renal transplantation (n = 5) were not different from those in patients with normal renal function. Renal function (n = 5) elimination half-life increased from 112 +/- 12 min (mean +/- SD) to 379 +/- 162 min, and serum clearance decreased from 9 +/- 2 ml/kg/min to 2 +/- 0.6 ml/kg/min in anephric patients (n = 4). We conclude that renal function accounts for 75% of pyridostigmine clearance.
在有和没有肾功能的麻醉患者中,在临床用作非去极化神经肌肉阻滞拮抗剂的条件下,研究了吡啶斯的明的动力学。通过气液色谱法测定吡啶斯的明血清水平,并将数据拟合到二室动力学模型。肾移植患者(n = 5)的吡啶斯的明动力学与肾功能正常的患者无差异。无肾患者(n = 4)的肾功能消除半衰期从112±12分钟(平均值±标准差)增加到379±162分钟,血清清除率从9±2毫升/千克/分钟降至2±0.6毫升/千克/分钟。我们得出结论,肾功能占吡啶斯的明清除率的75%。